BridgeBio Pharma Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $502.1M | $221.9M | $9.3M | $77.6M | $69.7M | $8.2M | $40.6M |
| Cost of Revenue | — | $21.0M | $3.9M | $2.4M | $3.4M | $3.1M | — | — |
| Gross Profit | — | $481.1M | $218.0M | $6.9M | $74.2M | $66.6M | — | — |
| Gross Margin | — | 95.8% | 98.3% | 73.7% | 95.6% | 95.5% | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $452.0M | $506.5M | $455.7M | $399.5M | $451.0M | $337.0M | $209.9M |
| SG&A Expense | — | $531.2M | $288.9M | $150.6M | $143.2M | $192.2M | $145.7M | $94.4M |
| Operating Income | — | $-523.4M | $-593.0M | $-607.4M | $-512.2M | $-576.6M | $-474.5M | $-266.2M |
| Operating Margin | — | -104.2% | -267.2% | -6,528.8% | -659.6% | -827.1% | -5,752.0% | -656.4% |
| Interest Expense | — | — | $34.3M | $81.3M | $80.4M | $46.8M | $36.7M | $8.8M |
| Pretax Income | — | $-732.5M | $-542.2M | $-653.3M | $-484.7M | — | $505.5M | $288.6M |
| Income Tax Expense | — | $435.0K | $1.2M | $0 | $0 | — | — | — |
| Net Income | — | $-732.9M | $-543.3M | $-653.3M | $-484.7M | $-586.5M | $-505.5M | $-288.6M |
| Net Margin | — | -146.0% | -244.9% | -7,021.9% | -624.2% | -841.2% | -6,127.9% | -711.5% |
| EPS (Basic) | — | $-3.78 | $-2.88 | $-3.95 | $-3.26 | $-3.90 | $-3.80 | $-2.48 |
| EPS (Diluted) | — | $-3.78 | $-2.88 | $-3.95 | $-3.26 | $-3.90 | $-3.80 | $-2.48 |
| Shares Outstanding (Basic) | 193.9M | 191.5M | 186.1M | 162.8M | 147.5M | 144.4M | 118.0M | 123.7M |
| Shares Outstanding (Diluted) | 193.9M | 191.5M | 186.1M | 162.8M | 147.5M | 144.4M | 118.0M | 123.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |